Cargando…
Low-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Results of a prospective study
OBJECTIVE: To evaluate the efficacy and safety of low-dose (45 mg) intravesical bacille Calmette–Guérin (BCG) therapy in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC), as intravesical BCG is the most acceptable adjuvant therapy for NMI transitional cell carcinoma of the b...
Autores principales: | Nour, Hani H., Gobashy, Smair E., Kamal, Ahmad M., Elbaz, Ahmad G., Roshdy, Mamdouh A., Kamel, Ahmad I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656809/ https://www.ncbi.nlm.nih.gov/pubmed/26609440 http://dx.doi.org/10.1016/j.aju.2015.09.005 |
Ejemplares similares
-
Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis
por: Huang, Di, et al.
Publicado: (2019) -
Bacille Calmette-Guérin: An ophthalmic perspective
por: Jain, Manish, et al.
Publicado: (2022) -
Are Bacille Calmette-Guérin Skin Reactions the Most Important Correlates of Bacille Calmette-Guérin’s Specific and Nonspecific Effects?
por: Schaltz-Buchholzer, Frederik
Publicado: (2022) -
Will bacille Calmette-Guerin immunization arrest the COVID-19 pandemic?
por: Ehtesham, Nasreen Zafar, et al.
Publicado: (2020) -
Tuberculosis vaccines: beyond bacille Calmette–Guérin
por: McShane, Helen
Publicado: (2011)